Your browser doesn't support javascript.
loading
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program.
Janin, Maxime; Ortiz-Barahona, Vanessa; de Moura, Manuel Castro; Martínez-Cardús, Anna; Llinàs-Arias, Pere; Soler, Marta; Nachmani, Daphna; Pelletier, Joffrey; Schumann, Ulrike; Calleja-Cervantes, Maria E; Moran, Sebastian; Guil, Sonia; Bueno-Costa, Alberto; Piñeyro, David; Perez-Salvia, Montserrat; Rosselló-Tortella, Margalida; Piqué, Laia; Bech-Serra, Joan J; De La Torre, Carolina; Vidal, August; Martínez-Iniesta, María; Martín-Tejera, Juan F; Villanueva, Alberto; Arias, Alexandra; Cuartas, Isabel; Aransay, Ana M; La Madrid, Andres Morales; Carcaboso, Angel M; Santa-Maria, Vicente; Mora, Jaume; Fernandez, Agustin F; Fraga, Mario F; Aldecoa, Iban; Pedrosa, Leire; Graus, Francesc; Vidal, Noemi; Martínez-Soler, Fina; Tortosa, Avelina; Carrato, Cristina; Balañá, Carme; Boudreau, Matthew W; Hergenrother, Paul J; Kötter, Peter; Entian, Karl-Dieter; Hench, Jürgen; Frank, Stephan; Mansouri, Sheila; Zadeh, Gelareh; Dans, Pablo D; Orozco, Modesto.
Afiliación
  • Janin M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Ortiz-Barahona V; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • de Moura MC; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Martínez-Cardús A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Llinàs-Arias P; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Soler M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Nachmani D; Department of Medicine and Pathology, Cancer Research Institute, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Pelletier J; Molecular Mechanisms and Experimental Therapy in Oncology Program, Metabolism and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Schumann U; EMBL-Australia Collaborating Group, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Garran Road, Acton, ACT, 2601, Australia.
  • Calleja-Cervantes ME; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Moran S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Guil S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Bueno-Costa A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Piñeyro D; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Perez-Salvia M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Rosselló-Tortella M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Piqué L; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Bech-Serra JJ; Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • De La Torre C; Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
  • Vidal A; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
  • Martínez-Iniesta M; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.
  • Martín-Tejera JF; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
  • Villanueva A; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
  • Arias A; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
  • Cuartas I; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
  • Aransay AM; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
  • La Madrid AM; Centro de Investigación Bimédica en Red de Enfermedades hepáticas y Digestivas (CIBERehd), CIC bioGUNE, 801A Bizkaia Technology Park, 48160, Derio, Spain.
  • Carcaboso AM; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.
  • Santa-Maria V; Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.
  • Mora J; Preclinical Therapeutics and Drug Delivery Research Program, Fundacio Sant Joan de Deu, Barcelona, Catalonia, Spain.
  • Fernandez AF; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.
  • Fraga MF; Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.
  • Aldecoa I; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.
  • Pedrosa L; Institute of Oncology of Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), 33011, Oviedo, Spain.
  • Graus F; Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain.
  • Vidal N; Pathology-Brain Bank, Hospital Clínic de Barcelona-CDB-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.
  • Martínez-Soler F; Glioma and Neural Stem Cell Group and Translational Genomics and Targeted Therapeutics in Solid Tumors Team, IDIBAPS, Barcelona, Catalonia, Spain.
  • Tortosa A; Clinical and Experimental Neuroimmunology, IDIBAPS, Barcelona, Catalonia, Spain.
  • Carrato C; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
  • Balañá C; Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
  • Boudreau MW; Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
  • Hergenrother PJ; Department of Pathology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.
  • Kötter P; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916, Badalona, Barcelona, Catalonia, Spain.
  • Entian KD; Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
  • Hench J; Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
  • Frank S; Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany.
  • Mansouri S; Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany.
  • Zadeh G; Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland.
  • Dans PD; Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland.
  • Orozco M; Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.
Acta Neuropathol ; 138(6): 1053-1074, 2019 12.
Article en En | MEDLINE | ID: mdl-31428936
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ribosomas / Biosíntesis de Proteínas / Neoplasias Encefálicas / Epigénesis Genética / Glioma / Metiltransferasas / Proteínas Musculares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Acta Neuropathol Año: 2019 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ribosomas / Biosíntesis de Proteínas / Neoplasias Encefálicas / Epigénesis Genética / Glioma / Metiltransferasas / Proteínas Musculares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Acta Neuropathol Año: 2019 Tipo del documento: Article País de afiliación: España